X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (51) 51
humans (47) 47
gastroenterology and hepatology (41) 41
gastroenterology & hepatology (37) 37
female (28) 28
male (25) 25
adult (23) 23
middle aged (19) 19
gastrointestinal diseases (16) 16
crohns-disease (14) 14
crohn's disease (12) 12
risk (12) 12
united states (12) 12
young adult (12) 12
tumor necrosis factor-alpha - antagonists & inhibitors (11) 11
ulcerative-colitis (11) 11
inflammatory bowel disease (10) 10
infliximab (10) 10
adolescent (9) 9
inflammatory bowel diseases - drug therapy (9) 9
inflammatory-bowel-disease (9) 9
retrospective studies (9) 9
united states food and drug administration (9) 9
adverse drug reaction reporting systems (8) 8
management (8) 8
risk factors (8) 8
ulcerative colitis (8) 8
aged (7) 7
colitis (7) 7
crohn disease - diagnostic imaging (7) 7
pharmacology & pharmacy (7) 7
surgery (7) 7
abridged index medicus (6) 6
crohn’s disease (6) 6
diagnosis (6) 6
drug therapy, combination (6) 6
mr enterography (6) 6
severity of illness index (6) 6
therapy (6) 6
tumor necrosis factor (6) 6
arthritis, rheumatoid - drug therapy (5) 5
crohn disease - drug therapy (5) 5
gastrointestinal agents - therapeutic use (5) 5
magnetic resonance imaging (5) 5
medical research (5) 5
medicine & public health (5) 5
obesity (5) 5
tomography, x-ray computed (5) 5
treatment outcome (5) 5
aged, 80 and over (4) 4
analysis (4) 4
antibodies, monoclonal, humanized - therapeutic use (4) 4
cancer (4) 4
care and treatment (4) 4
colon - pathology (4) 4
colonoscopy (4) 4
crohn disease - pathology (4) 4
ct enterography (4) 4
endoscopy (4) 4
gastroenterology (4) 4
inflammatory bowel diseases (4) 4
internal medicine (4) 4
intestine, small - pathology (4) 4
medicine, experimental (4) 4
odds ratio (4) 4
prevalence (4) 4
rheumatoid-arthritis (4) 4
tumor necrosis factor-alpha/antagonists and inhibitors (4) 4
tumors (4) 4
united states - epidemiology (4) 4
adverse drug reaction reporting systems - statistics & numerical data (3) 3
anti-inflammatory agents, non-steroidal - therapeutic use (3) 3
antibodies, monoclonal - therapeutic use (3) 3
azathioprine (3) 3
azathioprine - adverse effects (3) 3
case-control studies (3) 3
child (3) 3
colitis, ischemic - chemically induced (3) 3
colitis, ulcerative - diagnostic imaging (3) 3
colitis, ulcerative - drug therapy (3) 3
complications (3) 3
complications and side effects (3) 3
computed tomography (3) 3
computed-tomography (3) 3
crohn disease - complications (3) 3
crohn disease - therapy (3) 3
digestive system diseases (3) 3
double-blind (3) 3
drug therapy (3) 3
drug-related side effects and adverse reactions (3) 3
etanercept (3) 3
gastrointestinal agents - adverse effects (3) 3
hepatology (3) 3
immunosuppressive agents - adverse effects (3) 3
inflammation (3) 3
inflammatory bowel diseases - chemically induced (3) 3
inflammatory bowel diseases - complications (3) 3
inflammatory bowel diseases - diagnosis (3) 3
intestine, small - diagnostic imaging (3) 3
magnetic resonance imaging - methods (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Drug Design, Development and Therapy, ISSN 1177-8881, 11/2016, Volume 10, pp. 3685 - 3698
Crohn's disease is characterized by a dysregulation of both innate and adaptive immunity responses. Interleukin-12/23 (IL-12/23) pathway has been found to be a... 
Inflammatory bowel disease | Interleukin-12/23 monoclonal antibody | Ustekinumab | Interleukin-12 | Interleukin-23 | Crohn’s disease | interleukin-12/23 monoclonal antibody | CHEMISTRY, MEDICINAL | Crohn's disease | inflammatory bowel disease | ACTIVE PSORIATIC-ARTHRITIS | MAINTENANCE THERAPY | interleukin-12 | interleukin-23 | INTERLEUKIN-12/23 MONOCLONAL-ANTIBODY | ustekinumab | INFLAMMATORY-BOWEL-DISEASE | SUBCUTANEOUS USTEKINUMAB | INDUCTION THERAPY | TNF THERAPY | BIOLOGIC THERAPIES | DOUBLE-BLIND | PYODERMA-GANGRENOSUM | PHARMACOLOGY & PHARMACY | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Ustekinumab - pharmacology | Interleukin-12 - metabolism | Ustekinumab - chemistry | Ustekinumab - therapeutic use | Interleukin-23 - metabolism | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Interleukin-23 - antagonists & inhibitors | Arthritis, Psoriatic - drug therapy | Crohn Disease - drug therapy | Interleukin-12 - antagonists & inhibitors | Crohn Disease - physiopathology | Ustekinumab - administration & dosage | Antibodies, Monoclonal, Humanized - chemistry | Care and treatment | Immunotherapy | Patient outcomes | Methods | Interleukin | Immunoglobulin G | Clinical trials | Interleukin 23 | Arthritis | Drug development | Cell surface | Immunity | Immunology | Lymphocytes | Safety engineering | Gastroenterology | Remission | Tumor necrosis factor-TNF | Colon | Drug dosages | Medical research | Immune response | Psoriasis | Cytokines | Dendritic cells | Medical treatment | Interleukin 12 | Pharmacology | Inflammation | Adaptive immunity | FDA approval | Crohns disease | Monoclonal antibodies | Ligands | Pharmacokinetics
Journal Article
Gastrointestinal endoscopy clinics of North America, 07/2019, Volume 29, Issue 3, p. 447
Journal Article
Obesity Surgery, ISSN 0960-8923, 4/2018, Volume 28, Issue 4, pp. 1007 - 1014
Journal Article
Alimentary pharmacology & therapeutics, ISSN 0269-2813, 07/2020, Volume 52, Issue 2, pp. 401 - 402
LINKED CONTENT This article is linked to Sagami et al papers. To view these articles, visit https://doi.org/10.1111/apt.15767 and... 
Ultrasound | Ultrasonic imaging | Ulcerative colitis
Journal Article
Inflammatory Bowel Diseases, ISSN 1078-0998, 09/2017, Volume 23, Issue 9, pp. E44 - E45
Journal Article
Gastrointestinal Endoscopy, ISSN 0016-5107, 2016, Volume 83, Issue 5, pp. 1005 - 1012
Journal Article
Gastroenterology, ISSN 0016-5085, 05/2019, Volume 156, Issue 6, pp. S-1140 - S-1141
Journal Article
American Journal of Gastroenterology, ISSN 0002-9270, 01/2013, Volume 108, Issue 1, pp. 99 - 105
OBJECTIVES: The risk of non-Hodgkin's lymphoma (NHL) with tumor necrosis factor alpha (TNF-alpha) inhibitors is unclear, whether related to concomitant... 
RHEUMATOID-ARTHRITIS | INFLAMMATORY-BOWEL-DISEASE | THERAPY | AZATHIOPRINE | RISK | INFLIXIMAB | GASTROENTEROLOGY & HEPATOLOGY | CANCER | MEDLINE | Azathioprine - therapeutic use | Lymphoma, T-Cell - chemically induced | Certolizumab Pegol | United States | Humans | Immunoglobulin Fab Fragments - adverse effects | Immunosuppressive Agents - therapeutic use | Middle Aged | Antibodies, Monoclonal - adverse effects | Polyethylene Glycols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Immunoglobulin Fab Fragments - therapeutic use | Polyethylene Glycols - therapeutic use | Receptors, Tumor Necrosis Factor - therapeutic use | Etanercept | Infliximab | Arthritis, Rheumatoid - drug therapy | Mercaptopurine - therapeutic use | Aged, 80 and over | Adult | Female | Drug Therapy, Combination | Odds Ratio | United States Food and Drug Administration | Inflammatory Bowel Diseases - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | SEER Program | Antibodies, Monoclonal, Humanized - therapeutic use | Psoriasis - drug therapy | Adverse Drug Reaction Reporting Systems | Risk Factors | Spondylitis, Ankylosing - drug therapy | Mercaptopurine - adverse effects | Immunoglobulin G - therapeutic use | Immunoglobulin G - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Immunosuppressive Agents - adverse effects | Aged | Adalimumab | Azathioprine - adverse effects | Tumor Necrosis Factor-alpha - antagonists & inhibitors
Journal Article
世界胃肠病学杂志:英文版, ISSN 1007-9327, 2011, Volume 17, Issue 21, pp. 2681 - 2682
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.